A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome | Zendy

Daniela Caronia | Zendy; Miguel Martín | Zendy; Javier Sastre | Zendy; Julio de la Torre | Zendy; José Á. García-Sáenz | Zendy; María R. Alonso | Zendy; Leticia T. Moreno | Zendy; Guillermo Pita | Zendy; Eduardo DíazRubio | Zendy; Javier Benı́tez | Zendy; Anna GonzálezNeira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

Author(s) -

Daniela Caronia,

Miguel Martín,

Javier Sastre,

Julio de la Torre,

José Á. García-Sáenz,

María R. Alonso,

Leticia T. Moreno,

Guillermo Pita,

Eduardo DíazRubio,

Javier Benı́tez,

Anna GonzálezNeira

Publication year - 2011

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-10-1741

Subject(s) - cytidine deaminase , capecitabine , deoxycytidine , activation induced (cytidine) deaminase , medicine , cytidine , biology , genetics , cancer research , cancer , gemcitabine , gene , enzyme , colorectal cancer , somatic hypermutation , biochemistry , antibody , b cell

Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer. We investigated the association between grade 3 HFS and genetic variations in genes involved in capecitabine metabolism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research